Beckley Psytech Raises £14m ($18.6m) to Advance Development of 5-MeO-DMT for Neuropsychiatric Diseases

Beckley Psytech has raised $18.6 million to advance 5-MeO-DMT (and third-generation follow-ups) through trials and hopes to have it be approved by 2025. Investors in the current round include Noetic and Bail Capital.

Category Press Release Investment
Published in Psilocybin Alpha
Country United Kingdom

Companies Featured

Beckley Psytech
Beckley Psytech is working on getting 5-MeO-DMT to market as the first of a variety of psychedelic medicines.

Noetic is a prolific psychedelic venture fund that invests in startups in the wellness and psychedelic space.

People Featured

Cosmo Feilding Mellen
Cosmo Feilding Mellen is the Director & CEO of Beckley PsyTech. Previously he worked at the Beckley Foundation (with his mother Amanda Feilding) and co-founded Beckley Canopy Therapeutics.

Article Author

Josh Hardman
Josh Hardman is the mind behind Psychedelic Alpha, and one of the leading writers covering the implementation of psychedelics as medicine.